Humacyte, Inc. (NASDAQ:HUMAW) Short Interest Update
by Tristan Rich · The Markets DailyHumacyte, Inc. (NASDAQ:HUMAW – Get Free Report) saw a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 4,345 shares, a decrease of 22.4% from the November 30th total of 5,597 shares. Based on an average daily volume of 7,513 shares, the days-to-cover ratio is currently 0.6 days. Based on an average daily volume of 7,513 shares, the days-to-cover ratio is currently 0.6 days.
Humacyte Stock Down 10.4%
Shares of HUMAW traded down $0.01 during trading hours on Tuesday, reaching $0.09. 64,933 shares of the company traded hands, compared to its average volume of 20,076. The stock’s fifty day moving average price is $0.15 and its 200 day moving average price is $0.28. Humacyte has a 12-month low of $0.08 and a 12-month high of $2.14.
About Humacyte
Humacyte, Inc (NASDAQ:HUMAW) is a clinical-stage biotechnology company specializing in the development and manufacture of human acellular vessels (HAVs). These off-the-shelf, bioengineered vascular conduits are designed to serve as living implants for patients requiring vascular access, including those undergoing hemodialysis, as well as for peripheral artery disease and vascular trauma. Humacyte’s proprietary tissue-engineering platform leverages human vascular cells cultured on biodegradable scaffolds, which are subsequently decellularized to produce durable, non-immunogenic vessels that support natural tissue regeneration.
Founded in 2007 and headquartered in Durham, North Carolina, Humacyte has advanced its lead candidate, the HAV, through multiple clinical trials in the United States and Europe.